Nectrisine

Nectrisine (up to 5.0×10^-4 M; 1 h/30 min) potently inhibits yeast α-glucosidase (IC₅₀ = 4.8×10^-8 M) and demonstrates decreasing inhibitory activity against jack bean α-mannosidase, snail β-mannosidase, almond β-glucosidase, and bovine kidney β-N-acetylglucosaminidase, while having no effect on jack bean β-galactosidase, Fusarium oxysporum α-fucosidase, or Clostridium perfringens neuraminidase at concentrations up to 5.0×10^-4 M^[1].
Nectrisine (0.4 μM; 1 h/1 h) potently inhibits rat liver microsomal trimming glucosidase I with an IC₅₀ of 0.4 μM, demonstrating 3- to 6-fold greater potency than castanospermine and 1-deoxynojirimycin^[1].
Nectrisine (0.2×10^-6-5.0×10^-6 M; 1 h/30 min) acts as a glucose analogue that binds to the glucose-binding site of yeast α-glucosidase, exhibiting competitive inhibition (K_i=1.4×10^-7 M) when added simultaneously with substrate and noncompetitive inhibition (K_i=8.1×10^-8 M) after 1 h of enzyme preincubation^[1].
Nectrisine (20 mg/mL; 24 h) binds tightly to yeast α-glucosidase, with minimal reversal of inhibition observed even after 24 h of dialysis at 4°C^[1].
Nectrisine (0.13-500 μg/mL; 16 h) suppresses syncytium formation in NDV-infected BHK cells with an MIC of 1.9 μM (0.25 μg/mL) without reducing total HANA glycoprotein synthesis^[1].
Nectrisine (4 μg/mL; 16 h) profoundly suppresses hemolytic activity in NDV-infected BHK cells while having minimal effect on total or cell surface expression of HANA glycoprotein^[1].
Nectrisine induces Ia antigen expression with an EC₇₀ of 0.04 μg/mL in a cell-based immunomodulatory assay^[2].
Nectrisine potently inhibits yeast α-glucosidase (IC₅₀=0.04 μM), with weaker inhibitory activity against almond β-glucosidase (IC₅₀=2.2 μM), jack bean α-mannosidase (IC₅₀=3 μM), and snail β-mannosidase (IC₅₀=42 μM), and no activity against jack bean β-galactosidase^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.